Cargando…

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

Detalles Bibliográficos
Autores principales:	de la Puente, P, Muz, B, Jin, A, Azab, F, Luderer, M, Salama, N N, Azab, A K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771970/ https://www.ncbi.nlm.nih.gov/pubmed/26918363 http://dx.doi.org/10.1038/bcj.2016.7

Ejemplares similares

Molecularly Targeted Therapies in Multiple Myeloma
por: de la Puente, Pilar, et al.
Publicado: (2014)

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells
por: Muz, B, et al.
Publicado: (2014)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
por: von Euw, Erika, et al.
Publicado: (2012)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts
por: Lieu, Christopher H., et al.
Publicado: (2015)

TAK-733 inhibits inflammatory neointimal formation by suppressing proliferation, migration, and inflammation in vitro and in vivo
por: Park, Jun-Hee, et al.
Publicado: (2018)

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib
por: Muz, Barbara, et al.
Publicado: (2015)

Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using (18)F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549
por: Ishino, Seigo, et al.
Publicado: (2015)

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
por: Muz, Barbara, et al.
Publicado: (2015)

E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma
por: Maksimos, Mina, et al.
Publicado: (2023)

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021)

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
por: Muz, Barbara, et al.
Publicado: (2019)

Biological Insights into Myeloma and Other B Cell Malignancies
por: Fulciniti, Mariateresa, et al.
Publicado: (2016)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
por: Federico, Cinzia, et al.
Publicado: (2020)

Myeloma–Bone Interaction: A Vicious Cycle via TAK1–PIM2 Signaling
por: Harada, Takeshi, et al.
Publicado: (2021)

Targeting E-selectin to Tackle Cancer Using Uproleselan
por: Muz, Barbara, et al.
Publicado: (2021)

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy
por: Sun, Jennifer, et al.
Publicado: (2022)

TAK1 Phosphorylates RASSF9 and Inhibits Esophageal Squamous Tumor Cell Proliferation by Targeting the RAS/MEK/ERK Axis
por: Shi, Hui, et al.
Publicado: (2021)

CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation
por: Griesmann, Heidi, et al.
Publicado: (2021)

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2017)

Complete Draft Genome Sequence of Escherichia coli JF733
por: Kleiner, Gabriele R. M., et al.
Publicado: (2016)

The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation
por: Alao, John P, et al.
Publicado: (2009)

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2018)

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
por: Alcon, Clara, et al.
Publicado: (2022)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
por: Funck-Brentano, Elisa, et al.
Publicado: (2020)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
por: Sun, Jennifer, et al.
Publicado: (2021)

733 Vancomycin-Resistant Enterococcus (VRE) faecium Bloodstream Infections and Mortality
por: Suleyman, Geehan, et al.
Publicado: (2014)

The NK1 antagonist L-733,060 facilitates sequence learning
por: Favila, Natalia, et al.
Publicado: (2023)

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma
por: Chang-Yew Leow, C, et al.
Publicado: (2013)

Effect of leaf position and days post-infiltration on transient expression of colorectal cancer vaccine candidate proteins GA733-Fc and GA733-FcK in Nicotiana benthamiana plant
por: Kim, Kibum, et al.
Publicado: (2021)

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan
por: Håland, Erling, et al.
Publicado: (2021)

SUN-733 Analysis of Divergent Long Noncoding RNAs in Estrogen-Regulated Transcription
por: Lee, Debra, et al.
Publicado: (2020)

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
por: ANDERSEN, NICHOLAS J., et al.
Publicado: (2015)

Anti-Inflammatory Activity of Natural Products
por: Azab, Abdullatif, et al.
Publicado: (2016)

TAK1 inhibition increases proliferation and differentiation of chick retinal cells
por: Carrillo, Casandra, et al.
Publicado: (2022)

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination
por: Sahin, I, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bkpv124cdbffduqsib7v00imgc